therapeutics

Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026

April 26, 2026 12:00 ET  | Source: Oruka Therapeutics, Inc. MENLO PARK, Calif., April 26, 2026 (GLOBE NEWSWIRE) -- Oruka…

2 days ago

Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy

AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biopharmaceutical company…

4 days ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 24, 2026 08:00 ET  | Source: Aligos Therapeutics SOUTH SAN FRANCISCO, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Aligos…

4 days ago

Vivos Therapeutics Reports Full Year 2025 Financial Results

April 15, 2026 16:20 ET  | Source: Vivos Therapeutics, Inc Full Year 2025 revenue increased 16% Integration of The Sleep…

2 weeks ago

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026

Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026 Halle (Saale) / Munich,…

2 weeks ago

Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative personalized off-the-shelf immunotherapy toward clinical development

April 14, 2026 03:30 ET  | Source: Asgard Therapeutics Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s…

2 weeks ago

AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer

TAIPEI, April 13, 2026 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotechnology company focused on precision oncology, today announced that two…

2 weeks ago

Pelthos Therapeutics Announces CFO Transition

Senior Vice President, Finance & Accounting John M. Gay named Chief Financial Officer April 10, 2026 17:00 ET  | Source:…

2 weeks ago

Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares

April 06, 2026 10:53 ET  | Source: Celldex Therapeutics, Inc. HAMPTON, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics,…

3 weeks ago

Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium

April 02, 2026 08:00 ET  | Source: Tvardi Therapeutics HOUSTON, April 02, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi”)…

4 weeks ago